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We report three patients infected with unique strains of
vancomycin-dependent enterococci. Two were first infected
by genetically identical strains of vancomycin-resistant
enterococci (VRE). All three patients had much greater
exposure to vancomycin and third-generation cephalo-
sporins than did two control groups (patients infected with
VRE and hospitalized patients without enterococcal infec-
tions). While antimicrobial pressure promotes nosocomial
colonization by VRE, prolonged exposure to vancomycin
may foster the transition from vancomycin resistance to
dependence. 
V
ancomycin-resistant enterococci (VRE) are major no-
socomial pathogens worldwide (1). Recent case
reports, however, describe nosocomial infections caused by
enterococci that require vancomycin for growth (2–12).
Since 1993, we have identified three patients in our center
infected by vancomycin-dependent enterococci (VDE). We
report the microbiologic features and molecular epidemiol-
ogy of nosocomial infection caused by these organisms.
Methods
Enterococci showing growth on media containing 6
µg/mLof vancomycin and an MIC >8 µg/mLwere consid-
ered vancomycin-resistant. Strains unable to grow in the
absence of vancomycin 6 µg/mL, despite multiple subcul-
tures, were considered vancomycin-dependent. 
The genotypic basis of vancomycin resistance was
determined by using polymerase chain reaction to amplify
sequences coding for resistance, using oligonucleotide
primers for vanA (5'CATGAATAGAATAAAAGTTGC and
5'CTTATCACCCCTTTAACG, Department of Pharma-
cology, University of Wisconsin-Madison, Madison, WI)
and vanB (5'AAATTCGATCCGCACTACATC and 5'AA-
CGATGCCGCCATCCTCCTG, University of Wisconsin
Bio-technology Center, Madison, WI). Susceptibility was
assessed by National Committee for Clinical Laboratory
Standards criteria using Mueller-Hinton II agar (BBL,
Becton-Dickinson, Cockeysville, MD) containing van-
comycin 6 µg/mL. The capacity of D-alanyl-D-alanine to
support growth of the VDE was tested by using 2.5-mg and
5-mg disks of D-alanyl-D-alanine on Mueller-Hinton II
agar. Screening for revertants was performed by plating
serial dilutions of an overnight culture of VDE in van-
comycin-containing broth to Mueller-Hinton II agar with
and without vancomycin, which was incubated for 48 hours
at 35°C. Molecular relation of strains was determined by
using pulsed-field gel electrophoresis (PFGE) after diges-
tion of genomic DNA with restriction endonuclease Sma1
(Gibco BRL, Promega, Madison, WI) (13). 
Case Reports
Patient 1
A 32-year-old woman with long-standing type 1 dia-
betes mellitus and end-stage renal disease was admitted for
a kidney-pancreas transplant. Postoperatively, she had
multiple complications, including transplant renal failure
and intraperitoneal infection caused by vancomycin-resist-
ant  Enterococcus faecium. She received vancomycin,
teicoplanin, imipenem, amikacin, cefazolin, ceftazidime,
ciprofloxacin, gentamicin, metronidazole, ticarcillin-
clavulanate, trimethoprim-sulfamethoxazole, and intra-
venous amphotericin B. On hospital day 53, intra-
abdominal fluid specimens obtained at surgery yielded
vancomycin-resistant  E. faecium that did not grow on
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USAtreated with surgical drainage and a combination of
teicoplanin and gentamicin. Despite this, the patient died of
refractory sepsis on hospital day 268. VDE were isolated
from multiple intraabdominal cultures in the month before
death.
Patient 2 
A40-year-old woman with type 1 diabetes mellitus and
end-stage renal disease received a kidney-pancreas trans-
plant, which was complicated by multiple intraabdominal
abscesses that were drained surgically. On posttransplant
day 82, VRE were isolated from intraabdominal cultures.
The transplanted kidney was removed on posttransplant
day 115 and the transplanted pancreas 10 days later.
However, the patient continued to show signs of sepsis.
Blood cultures were positive on radiometric monitoring.
Subculturing onto media containing vancomycin con-
firmed bacteremia with a strain of E. faecium that did not
grow in the absence of vancomycin. The patient remained
critically ill, despite prolonged therapy with intravenous
quinupristin-dalfopristin, and died after 4 days of refracto-
ry VDE bacteremia, 132 days after transplantation.
Patient 3 
A 47-year-old woman with chronic myelogenous
leukemia received a matched-unrelated donor bone mar-
row transplant. Subsequently, when severe graft-versus-
host disease, acute renal failure, cyclosporine
neurotoxicity, prolonged respiratory failure, and bac-
teremia with Corynebacterium spp. resistant to β-lactam
antimicrobial agents developed, the patient received a pro-
longed course of vancomycin. On hospital day 80, when
vancomycin-containing media was used, she was found to
have catheter-associated urinary tract infection with a
strain of enterococcus that required vancomycin for
growth. Efforts were not made to eradicate VDE from the
urine. The patient ultimately died of refractory graft-ver-
sus-host disease with multiple organ dysfunction syn-
drome on posttransplant day 87.
Case-Control Study
Potential risk factors for nosocomial infection were
compared in the 3 patients and 10 randomly selected
patients with nosocomial infection caused by VRE and 10
at-risk, concurrently hospitalized patients not infected by
enterococci. Controls were matched by age and admission
to the same hospital service as patients in the VRE cohort.
Results
PFGE analysis indicated that the three strains of van-
comycin-dependent enterococci were clonally distinct
(Figure 2) when the criteria of Tenover et al. were used
(14). In the two cases in which strains of VRE were isolat-
ed before VDE were first detected, the restriction fragment
patterns of the initial VRE strain and subsequent VDE iso-
late were identical.
All three strains of VDE were E. faecium; two were
genotype vanA, and one was vanB. All showed resistance to
penicillin, ampicillin, amoxicillin-clavulanate, gentamicin,
and erythromycin. All were susceptible to quinupristin-dal-
fopristin; two were intermediately susceptible, and one was
susceptible to teicoplanin. The rate of spontaneous rever-
sion to nondependence on vancomycin was 1.2 x 10
–6 for
strain 1, 2.5 x 10
–6 for strain 2, and 2.6 x 10
–3 for strain 3.
Growth of VDE was not supported by D-alanyl-D-alanine.
All three patients infected by VDE were female trans-
plant recipients and experienced posttransplant acute renal
failure; by contrast, the VRE group had lower exposure to
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Figure 1. Etest (AB Biodisk, Solna) vancomycin susceptibility–test-
ing strip on sheep-blood agar inoculated with vancomycin-depend-
ent enterococci (VDE). VDE strain can only grow contiguous to the
end of the strip with the highest concentrations of vancomycin.
Isolated colonies are also growing far from the strip; they repre-
sent revertants to vancomycin independence.the intensive care unit (Table). No other significant differ-
ences were noted between the two groups of patients with
enterococcal infection and the group of at-risk controls in
underlying conditions, severity of illness, or exposure to
invasive devices. However, in the 60 days before onset of
the nosocomial enterococcal infection, major differences
in exposure to antimicrobial agents occurred: mean ± stan-
dard deviation (SD) total antimicrobial days 103 ± 40 for
VDE, 86 ± 31 for VRE, and 28.6 ± 23.1 for noninfected
controls (VDE or VRE vs. controls, p < 0.01), especially
vancomycin (27 ± 14 days for VDE, 9 ± 10 for VRE, and
5.7 ± 7.6 for controls; VDE vs. VRE, p = 0.03) and third-
generation cephalosporins (17.0 ± 11.4 days for VDE, 15.6
± 11.9 for VRE, and 2.9 ± 4.8 for noninfected controls;
VDE or VRE vs. controls, p < 0.01). All 3 patients with
VDE infection died during hospitalization, contrasted with
3 of 10 patients infected with VRE and 2 of 10 uninfected
control patients who died (p = 0.03).
Discussion
Vancomycin resistance is thought to be mediated pri-
marily by the strain’s acquiring the capacity to synthesize
the cell wall by using D-alanine-D-lactate (1). In the first
clinical reports of VDE infection, Fraimow et al. (2) and
Green et al. (4) independently reported that D-alanyl-D-
alanine supported the growth of a vancomycin-dependent
E. faecalis strain (2) and a vanB E. faecium strain (4),
respectively; Sng et al. (9) quantified the amount of D-
alanyl-D-alanine required to support growth of their VDE
strain. The phenomenon of vancomycin dependence may
derive from the loss of a D-alanyl-D-alanine ligase in a
VRE strain, which is then unable to survive unless van-
comycin induces the production of D-alanine-D-lactate
ligase (2,4). Previous reports (2–12) and our experience
(Figure 2) suggest that infecting strains of VRE make the
transition in situ to a state of vancomycin dependence only
after prolonged exposure to vancomycin.
Sixteen patients infected by enterococci dependent on
vancomycin for growth have been reported (2–12). In
every case with data reported on prior antimicrobial expo-
sure, the patients had also received a glycopeptide, van-
comycin, or teicoplanin. We sought to minimize the effect
of control group bias (15) by selecting as a control group
concurrently hospitalized patients at risk for nosocomial
infection with VRE or VDE but not infected with entero-
cocci. We found that intense use of third-generation
cephalosporins was the most important risk factor for both
VDE and VRE when compared with the uninfected control
group. This finding is in line with our recent observation of
the striking commonality of risk factors for nosocomial
colonization and infection with a diverse array of multire-
sistant pathogens, in particular, heavy exposure to third-
generation cephalosporins (16). Selection pressure from
broad-spectrum antimicrobial agents apears to promote
nosocomial colonization with VRE, which, after prolonged
exposure to vancomycin, may lead to the emergence of
vancomycin dependence in the colonizing strain.
Renal insufficiency was the other risk factor identified
in our study. The ecologic impact of vancomycin exposure
is magnified and extended in patients with renal
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Figure 2. Pulsed-field gel electrophoresis of the three strains of
vancomycin-dependent enterococci (VDE) and, in two cases, a
vancomycin-resistant enterococci (VRE) strain isolated before the
VDE in the same patient. The three VDE strains appear to be
genetically distinct, although two may be related. In both cases in
which VRE was isolated before VDE, VRE and subsequent VDE
strains appear genetically identical. RFLP, restriction fragement
length polymorphism; MW, molecular weight; l, lambda ladder, Y,
yeast chromosome marker.insufficiency, especially those with end-stage renal disease
requiring hemodialysis (all 3 of our patients and 5 of the 16
previously reported cases), where a single dose persists in
the patient’s body for many days. The emergence of novel
strains of Staphylococcus aureus exhibiting resistance to
vancomycin has also been reported in this clinical setting
(17). The prevalence of nosocomial infection or coloniza-
tion with VDE can only be determined by the use of media
containing vancomycin when processing cultures from
patients at risk for VDE infection, namely those who have
had prolonged exposure to vancomycin or third-generation
cephalosporins, especially if they are already known to be
colonized or infected by VRE.
These infections are clearly not trivial, although their
clinical importance remains to be fully determined. Five
of the 16 previously reported VDE infections were bac-
teremias (4,7,9,11). VDE was considered the immediate
cause of death in one of our patients and a contributory
cause in another. Green et al. (4) reported the spontaneous
reversion of VDE to nondependence at 1 in 10
6, which we
confirmed in all three of our strains. Thus, vancomycin
discontinuation alone may not be sufficient to treat
patients with VDE infection, especially if the patient has
renal failure.
The best management of infection with VDE—beyond
source control and treatment with linezolid, quinupristin-
dalfopristin, or daptomycin—remains to be determined.
More effective antimicrobial stewardship policies are
needed to prevent VDE, VRE, and other resistant nosoco-
mial pathogens from emerging.
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(n = 3) 
VRE 
(n = 10) 
Uninfected control  
patients (n = 10) 
Age, y, mean ± SD  39.0±7.5  41.7± 20.2  51.1±13.0 
Sex, no.   
Male  0  5  7 
Female  3  5  3 
Duration of hospitalization, days, mean ± SD  41.7±13  33.6±12.1  37.6±44.7 
ICU stay, days, mean ± SD  9.3±4.0  1.0±1.9
b  7.4±7.4 
Site of nosocomial enterococcal infection   
Primary bloodstream infection  0  5  0 
Surgical wound infection  1  2  0 
Intraabdominal infection  1  1  0 
Urinary tract Infection  1  1  0 
Service, no.   
Medicine or pediatrics  1  5  5 
Surgery  2  5  5 
Associated conditions, no.   
Malignancy  1  4  2 
Diabetes mellitus  2  3  4 
Renal failure  3  3  4 
Trauma   0  2  0 
Transplant recipient  3  4  2 
APACHE II score, mean ± SD  18.7±2.1  15.1±6.7  19.4±10.0 
Serum creatinine, mg/dL, mean ± SD  2.8±0.5
c  1.5±0.8  1.9±1.8 
Days antimicrobial agent administered   
Vancomycin  27.3±13.7
d  9.1±10.3  5.7±7.6 
Aminoglycosides  11.3±6.7  9.7±9.8  2.5±5.1 
First- or second-generation cephalosporins  0.7±0.6  1.1±2.2  3.6±7.5 
Third-generation cephalosporins  17.0±11.4
e  15.6±11.9
f  2.9±4.8 
Quinolones  10.3±5.5  8.0±9.2  3.4±4.8 
Clindamycin  2.3±4.0  7.1±11.7  1.2±3.8 
Metronidazole  4.3±7.5  4.4±6.3  1.8±3.8 
Trimethoprim-sulfamethoxazole  32.7±18.0
e  14.6±19.2  2.7±5.7 
Others  1.0±1.7  5.6±9.5  4.8±9.6 
Total  106.3±44.7
e  83.5±29.4
f  28.6±23.1 
aVDE, vancomycin-dependent enterococci; VRE, vancomycin-resistant enterococci; ICU, intensive care unit; APACHE, Acute Physiology and Chronic 
Health Evaluation score. 
bVRE vs. controls, p = 0.03. 
cVDE vs. VRE, p = 0.02. 
dVDE vs. VRE, p = 0.03. 
eVDE vs. controls, p < 0.01. 
fVRE vs. controls, p < 0.01. Acknowledgments
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